Fate Therapeutics, Inc. (FATE) Stock Analysis

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Thu, July 9, 2026 at 12:30 PM UTC 3 min read

Fate Therapeutics has received FDA clearance for its Investigational New Drug Application for the FT839 product candidate, marking a significant step in its clinical development. This approval allows the company to initiate clinical trials, which could potentially lead to new treatment options in the oncology space. For investors, this milestone enhances the company's growth prospects and may positively impact its stock performance as it advances its pipeline.

Read full article →

H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT

Wed, June 10, 2026 at 6:22 PM UTC 3 min read

H.C. Wainwright has reiterated its "Buy" rating on Fate Therapeutics (FATE) with a price target of $7. This endorsement reflects confidence in the company's potential for growth, particularly in its innovative cell therapy pipeline. For investors, this suggests a favorable outlook and potential upside in the stock, reinforcing the belief that FATE could deliver significant returns as it advances its clinical programs.

Read full article →